Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
出版年份 2020 全文链接
标题
Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
作者
关键词
-
出版物
Journal of the American Heart Association
Volume 9, Issue 18, Pages -
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2020-09-06
DOI
10.1161/jaha.120.016976
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Association of Urine Albumin Excretion With Incident Heart Failure Hospitalization in Community-Dwelling Adults
- (2019) Luke N. Bailey et al. JACC-Heart Failure
- The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
- (2019) Daniël H. van Raalte et al. DIABETES CARE
- New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
- (2018) Claire C. J. Dekkers et al. Current Diabetes Reports
- Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD
- (2018) Sophie M. van den Belt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
- (2018) Benjamin M. Scirica et al. JAMA Cardiology
- Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
- (2018) Mikhail Kosiborod et al. Cardiovascular Diabetology
- Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans
- (2017) Carmen A. Peralta et al. BMC Nephrology
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Is a reduction in albuminuria associated with renal and cardiovascular protection? Apost hocanalysis of the ALTITUDE trial
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Use of Clinical Decision Support to Improve Primary Care Identification and Management of Chronic Kidney Disease (CKD)
- (2016) Cara B. Litvin et al. Journal of the American Board of Family Medicine
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy
- (2015) T. F. Kropelin et al. Clinical Journal of the American Society of Nephrology
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials
- (2014) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- (2014) Bernard Zinman et al. Cardiovascular Diabetology
- Microalbuminuria: target for renoprotective therapy PRO
- (2014) Sara S. Roscioni et al. KIDNEY INTERNATIONAL
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Within-Person Variability in Kidney Measures
- (2013) Elizabeth Selvin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
- (2013) F. P. Brouwers et al. EUROPEAN HEART JOURNAL
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
- (2009) T. Ninomiya et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria
- (2008) E. C. Witte et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started